LAMIVUDINE HBV (lamivudine)
ANTIVIRAL-HIV(ANTIRETROVIRAL) NUCLEOSIDE/-TIDE RT INHIBITORS · CHRONIC HEPATITIS B
GSMS, INC.
Drug class
Oral Antivirals for Chronic Hepatitis B
Oral antivirals for chronic hepatitis B primarily consist of nucleoside and nucleotide analogues, including agents such as entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide. Read more about Oral Antivirals for Chronic Hepatitis B
19 drugs in this class 17 manufacturers
Drugs in Oral Antivirals for Chronic Hepatitis B
Filter & compare in the drug finder →
Opens the drug finder with Oral Antivirals for Chronic Hepatitis B preselected. Add indication or manufacturer filters there.
Oral antivirals for chronic hepatitis B primarily consist of nucleoside and nucleotide analogues, including agents such as entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide.
These agents function by selectively inhibiting the reverse transcriptase and DNA polymerase activities of the hepatitis B virus, thereby causing viral DNA chain termination and suppressing replication.
Clinically, they are used to manage chronic hepatitis B virus infection to achieve long-term viral suppression, normalize liver enzymes, reduce hepatic inflammation, and lower the risks of progressive fibrosis, cirrhosis, end-stage liver failure, and hepatocellular carcinoma.
-
nih.gov
Oral antivirals for chronic hepatitis B primarily consist of nucleoside and nucleotide analogues, including agents such as entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide
-
aasld.org
Oral antivirals for chronic hepatitis B primarily consist of nucleoside and nucleotide analogues, including agents such as entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide Clinically, they are used to manage chronic hepatitis B virus infection to achieve long-term viral suppression, normalize liver enzymes, reduce hepatic inflammation, and lower the risks of progressive fibrosis, cirrhosis, end-stage liver failure, and hepatocellular carcinoma
-
fda.gov
These agents function by selectively inhibiting the reverse transcriptase and DNA polymerase activities of the hepatitis B virus, thereby causing viral DNA chain termination and suppressing replication Clinically, they are used to manage chronic hepatitis B virus infection to achieve long-term viral suppression, normalize liver enzymes, reduce hepatic inflammation, and lower the risks of progressive fibrosis, cirrhosis, end-stage liver failure, and hepatocellular carcinoma
-
fda.gov
These agents function by selectively inhibiting the reverse transcriptase and DNA polymerase activities of the hepatitis B virus, thereby causing viral DNA chain termination and suppressing replication
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.